Skip to content
The Nexus
DossierENTITY

SK Group

Coverage of SK Group in the Nexus archive.

Earliest in view: Apr 23 · 09:00 UTCMost recent: Jul 11 · 09:00 UTC
Co-mentioned in this coverage
Recent coverage
  • BUSINESSJul 11 · 09:00 UTCFORTUNE
    How SK Hynix just pulled off the second-largest U.S. share sale by quietly powering the AI boom

    SK Hynix raised $26.5 billion in the second-largest U.S. share sale, listing on Nasdaq as the world’s leading high-bandwidth memory manufacturer. The IPO follows a 630% share surge in Korea and aims to address valuation discounts linked to South Korea’s chaebol governance, with U.S. investors gaining access to a key AI infrastructure provider.

  • BUSINESSJul 1 · 06:11 UTCCNBC TOP
    KKR to control South Korea's $1.3 billion renewables platform with SK as AI power demand rises

    KKR will control South Korea's $1.3 billion renewables platform alongside SK as AI power demand increases. The move follows South Korea's announcement of three major investment projects in semiconductors, physical AI, and AI data centers.

  • BUSINESSJun 29 · 07:25 UTCBLOOMBERG
    Korean Stocks Rebound as Samsung, SK Hynix Unveil Spending Plan

    Korean stocks rebounded as Samsung Electronics Co. and SK Hynix Inc. announced large-scale investments in memory chips, data centers, and robotics. The plan was unveiled alongside South Korea's President Lee Jae Myung during a news conference at the presidential Blue House.

  • BUSINESSJun 28 · 23:41 UTCFORTUNE
    Samsung, SK reportedly to invest $1.3 trillion over 10 years

    Samsung Group and SK Group plan to invest up to 2,000 trillion won ($1.3 trillion) over 10 years in sectors like semiconductors, AI data centers, and physical AI as part of South Korea’s 'Three Mega Projects for the Great Leap Forward' initiative. Investments include building semiconductor fabrication plants in Gwangju and expanding chip production facilities in Chungcheong provinces.

  • BUSINESSJun 22 · 21:00 UTCFORTUNE
    Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

    Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.

  • BUSINESSApr 23 · 09:00 UTCBLOOMBERG
    The Quiet AI Trade That’s Raking in Billions

    SK Hynix Inc. showcased its 12-layer HBM4 memory chips at the SK AI Summit in Seoul. Chey Tae Won, chairman of SK Group, predicted robust AI demand in the coming years, dismissing concerns about a spending bubble.

SK Group · Dossier · The Nexus